COMPANY PROFILE

Vericel

Explore full profile

Vericel Corporation | Expanded Cellular Therapies | CLI And DCM Clinical Research

Cambridge, United StatesFounded 1989Biotech & Life Sciences

Valuation $2.06B Market cap · 2026

Revenue $336M Latest reported FY

EBITDA $90M Latest reported FY

About Vericel

Vericel Corporation operates in the biotechnology sector, specializing in advanced cell therapies for the treatment of severe burns and knee cartilage repair. The company primarily serves healthcare providers, including hospitals and specialized clinics, focusing on patients with osteochondral defects and severe thermal burns. Vericel's business model revolves around the development, manufacturing, and commercialization of FDA-approved products like MACI and NexoBrid. MACI is a tissue-engineered product used to repair symptomatic cartilage damage in the knee, while NexoBrid is a botanical drug for the treatment of severe thermal burns. The company generates revenue through the sale of these specialized medical products, which are often covered by insurance due to their critical nature. Vericel operates in a niche market with high barriers to entry, providing it with a competitive edge. The company invests heavily in research and development to maintain its leadership in cell therapy solutions.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 1989
Headquarters: Cambridge, United States
Listing: IPO 1997
Employees: 518
Open positions: 17
Dealroom signal: 52.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITY✓Other financing	Jun 2018	$75M	—	Undisclosed	—
POST IPO EQUITYOther financing	Dec 2016	$20M	—	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$336M	+21.7%	$90M	26.8%	$29M	8.7%	$28M
2025	$276M	+16.5%	$30M	10.7%	$17M	6%	$28M
2024	$237M	+20.1%	$17M	7%	$10M	4.4%	$25M
2023	$198M	+20.2%	$2.9M	1.5%			$21M
2022	$164M	+5.2%	−$16M	-9.5%
2021	$156M	+25.8%	−$7.6M	-4.9%
2020	$124M	—	$3M	2.5%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Vericel website traffic

Latest recorded traffic for Vericel is 4.2K monthly website visits, down 10.6% over the last three months. Vericel's team grew 65.5% over the past year.

Latest monthly visits4.2K 3-month web change-10.6% 1-year team growth+65.5%

Monthly website visitsApr 2016–Mar 2021

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Sr. Manager, Promotional Planning & Marketing OperationsBurlington, Massachusetts, United States, Northern America, Americas · Marketing & Communication · Sep 6, 2026 Account Manager, Burn CareIrvine, CA · Sales · Sep 3, 2026 Director, Human ResourcesBurlington, MA · Human Resources · Aug 30, 2026 Administrative Assistant, ClinicalBurlington, MA · Other · Aug 28, 2026 Director, Facilities & EngineeringCambridge, Massachusetts, United States, Northern America, Americas · CSM & Support · Aug 21, 2026 Senior Medical Science Liaison - Orthopedics NortheastBloomington, IL · Other · Aug 12, 2026 Joint Restoration Territory ManagerBloomington, IL · Project Management · Aug 9, 2026 Maintenance Technician, ICambridge, MA · Other · Aug 8, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SSSecondWave SystemsDeveloping a novel, ultrasound-based wearable neuromodulation platform	Minneapolis, United States	Operational	19	$17M	$28M
FUFunPepFunPep is an Industry-university collaboration bioventure company	Ibaraki, Japan	Operational
AIArterial Health InternationalProvides clinical diagnostic tests for a comprehensive evaluation of cardiovascular disease risk factors	Atlanta, United States	Operational
LYLysoclearPremium laboratory research services for biotechnology and pharmaceutical companies, specializing in ocular toxicology and structural biology	Lafayette, United States	Operational
TBTAGCyx BiotechnologiesCreating candidate compounds for high-performance nucleic acid drugs with high affinity and specificity for target molecules using our proprietary nucleic acid basic technology	Tokyo, Japan	Acquired
ANAmygdala NeuroscienceAmygdala's mission is to address the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction	Palo Alto, United States	Operational
ATAnHeart TherapeuticsPrecision medicine biopharmaceutical company leveraging expertise in clinical research and development and product registration focusing initially on oncology products	Huangpu, China	Acquired
CBContraria BiotechDevelops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics	Siena, Italy	Operational